Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. An interim analysis revealed a double blow to the oral antibiotic candidate, which both failed to beat placebo and ...

Spero Therapeutics (NASDAQ:SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720. In a ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

It is hard to get excited after looking at Spero Therapeutics' (NASDAQ:SPRO) recent performance, when its stock has declined 7.6% over the past three months. However, a closer look at its sound ...

Nancy Spero was an American painter and feminist artist. Her expressive work is characterized by its figurative interpretation of sociopolitical and cultural issues, often directly tackling racism, ...

A Maryland native, Chef Johnny Spero staged around the world at restaurants such as Mugaritz and Noma prior to returning to the Washington, D.C. area and working for José Andrés’ Minibar.

Oct. 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare ...

The Spero-QT is the next breakthrough in label-free chemical imaging and represents the second generation of high-performance infrared microscopes powered by quantum cascade laser (QCL ...

Spero Therapeutics has suspended the development of its antibiotic SPR720, after the therapy failed to meet the primary endpoint in a Phase IIa trial in patients with non-tuberculous mycobacterial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...